Cannabis-focused research and development company The Green
Organic Dutchman Holdings (TSX: TGOD) (OTCQX: TGODF) today announced
appointment of Dr. Caroline MacCallum and Jacques Dessureault to its board of
directors. Per the update, Dr. MacCallum is one of the world’s most prominent
experts in cannabinoid-based medicine. At the University of British Columbia,
she is an internist, complex pain and cannabinoid clinician, researcher and
clinical instructor in the Department of Medicine, an adjunct professor in the
Faculty of Pharmaceutical Sciences Program and an associate member of the
Department of Palliative Care. Dr. MacCallum is also Greenleaf Medical Clinic’s
medical director, where she has assessed and developed cannabinoid treatment
plans for more than 3,000 patients across Canada. Jacques Dessureault has an
extensive pharmaceutical career with significant experience in life sciences,
over-the-counter, natural health, and technology industries. He has held
multiple leadership positions, including serving in an international role with
Novartis as its global marketing division head based in Basel, Switzerland, and
domestic senior executive roles as president and general manager of Valeant
Pharmaceutical Inc., vice president at Bristol Myer-Squibb and business unit
head and general manager at Novartis Canada. At Valeant Pharmaceuticals,
Dessureault led all Canadian commercial units including research and
development and international manufacturing and technical operations. In
addition, he held responsibilities for government relations and business
acquisitions, integrations and divestments.
“We are incredibly fortunate to add Dr. MacCallum and
Jacques Dessureault to our Board of Directors at such a pivotal time, as we
approach production ramp-up and our first commercial sales,” TGOD Chairman of
the Board Jeff Scott stated in the news release. “The TGOD Board now consists
of independent directors with the exception of our CEO. Both new additions
possess valuable skills and extensive experience that will greatly benefit TGOD
moving forward.”
To view the full press release, visit http://ibn.fm/3nw7T
About The Green Organic Dutchman Holdings Ltd.
The Green Organic Dutchman Holdings Ltd. is a premium global
organic cannabis company, with operations focused on legal medical cannabis
markets in Canada, Europe and Latin America and the legal Canadian adult-use
market. The company grows high quality, organic cannabis with sustainable,
all-natural principles. TGOD’s products are laboratory tested to ensure
patients have access to a standardized, safe and consistent product. TGOD has a
funded capacity of 170,000 kg and is building 1,382,000 sq. ft. of cultivation
facilities across Ontario, Quebec and Jamaica. In addition, TGOD
has raised approximately C$460 million and has over 20,000 shareholders. TGOD’s
Common Shares and warrants issued under the indenture dated November 1, 2017
trade on the TSX under the symbol “TGOD” and “TGOD.WT”, respectively. For more
information, visit the company’s website at www.TGOD.ca.
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
